Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation

Ann N Y Acad Sci. 1991:628:126-39. doi: 10.1111/j.1749-6632.1991.tb17230.x.

Authors

A E Bogden¹, P Carde, E D de Paillette, J P Moreau, M Tubiana, E Frindel

Affiliation

¹ Biomeasure Incorporated, Hopkinton, Massachusetts 07148.

PMID: 1648882
DOI: 10.1111/j.1749-6632.1991.tb17230.x

No abstract available

MeSH terms

Animals
Body Weight / drug effects
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Squamous Cell / drug therapy*
Cell Line
Cyclophosphamide / therapeutic use
Cyclophosphamide / toxicity*
Cytarabine / pharmacology
Cytarabine / toxicity*
Female
Growth Inhibitors / therapeutic use*
Hematopoietic Stem Cells / drug effects*
Humans
Immunologic Deficiency Syndromes / physiopathology
Lung Neoplasms / drug therapy*
Mice
Mice, Inbred BALB C
Mice, Nude
Neoplasm Transplantation
Oligopeptides / pharmacology
Oligopeptides / therapeutic use*
Transplantation, Heterologous

Substances

Growth Inhibitors
Oligopeptides
Cytarabine
Cyclophosphamide
goralatide